Synthesis and evaluation of second generation Flex-Het scaffolds against the human ovarian cancer A2780 cell line

被引:11
|
作者
Gnanasekaran, Krishna Kumar [1 ]
Benbrook, Doris Mangiaracina [2 ]
Nammalwar, Baskar [1 ]
Thavathiru, Elangovan [2 ]
Bunce, Richard A. [1 ]
Berlin, K. Darrell [1 ]
机构
[1] Oklahoma State Univ, Dept Chem, Stillwater, OK 74078 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Dept Obstet & Gynecol, Oklahoma City, OK 73104 USA
基金
美国国家科学基金会;
关键词
Second generation flexible heteroarotinoids; Flex-Hets; SHetA2; series; Anti-cancer agents; Ovarian cancer; RETINOIC ACID RECEPTOR; INDUCE APOPTOSIS; ANTITUMOR AGENT; X-RECEPTOR; HETEROAROTINOIDS; SHETA2; ANTICANCER; MITOCHONDRIA; SUFFICIENT; TOXICITY;
D O I
10.1016/j.ejmech.2015.03.070
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Flexible Heteroarotinoids (Flex-Hets) are a class of substituted di-aryl compounds that exhibit potent anti-cancer activity without toxicity. They were derived from the more conformationally restricted, 2-atom linker Hets by substitution of the 2-atom linker with a 3-atom urea or thiourea linker, which conferred more potent inhibitory activity against cancer cell lines. The objectives of this structure activity relationship (SAR) study were to determine if a 4-atom acrylamide linker and various substitutions on the terminal aryl ring altered the anti-cancer activity of these second generation Flex-Het compounds compared to the parent Flex-Het compound, SHetA2, which has a thiourea linker and a nitro substituent. Biological activity was measured using a cytotoxicity assay of the human A2780 ovarian cancer cell line treated with a range of compound concentrations. Nitrogen-based substitutions on the terminal aryl group caused similar, but slightly reduced efficacies and potencies. Exceptions were systems that had a nitro group at the para position, the potencies of which were better than that of SHetA2 with efficacies that were only slightly reduced compared to SHetA2. Similarly, the potency of the system with a para dimethylamino group was greater than that of SHetA2. However, a 30% reduction in efficacy compared to SHetA2 was noted. While specific members with the 4-atom acrylamide linker did exhibit excellent potency, the efficacy was slightly below that of SHetA2. Thus, a gradient of activities was observed as the substituent on the aryl ring was altered. (C) 2015 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:209 / 217
页数:9
相关论文
共 50 条
  • [21] Lectin array and glycogene expression analyses of ovarian cancer cell line A2780 and its cisplatin-resistant derivate cell line A2780-cp
    Ran Zhao
    Wenjun Qin
    Ruihuan Qin
    Jing Han
    Can Li
    Yisheng Wang
    Congjian Xu
    Clinical Proteomics, 2017, 14
  • [22] Molecular mechanism of apoptosis in A2780 cisplatin-resistant human ovarian cancer cell line promoted by H13
    季宇彬
    王宏亮
    李燕
    尤启东
    陈晓光
    哈尔滨商业大学学报(自然科学版), 2006, (03) : 1 - 4
  • [23] Ellagic Acid and Resveratrol Prevent the Development of Cisplatin Resistance in the Epithelial Ovarian Cancer Cell Line A2780
    Engelke, Laura H.
    Hamacher, Alexandra
    Proksch, Peter
    Kassack, Matthias U.
    JOURNAL OF CANCER, 2016, 7 (04): : 353 - 363
  • [24] TGF-β1 and IL-10 expression in epithelial ovarian cancer cell line A2780
    Feng, Xin
    Wang, Cai-Xia
    Ou, Zhi-Ying
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2015, 14 (12) : 2179 - 2185
  • [25] Human papillomavirus type 16 E6-enhanced susceptibility to apoptosis induced by TNF in A2780 human ovarian cancer cell line
    Vikhanskaya, F
    Falugi, C
    Valente, P
    Russo, P
    INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (06) : 732 - 739
  • [26] Paclitaxel resistance in the adriamycin-resistant ovarian cancer cell line A2780: Role of slco uptake transporters
    Svoboda, M.
    Roegelsperger, O.
    Wlcek, K.
    Liedauer, R.
    Jaeger, W.
    Thalhammer, T.
    ANNALS OF ONCOLOGY, 2007, 18 : 32 - 32
  • [27] LC-MS Based Sphingolipidomic Study on A2780 Human Ovarian Cancer Cell Line and its Taxol-resistant Strain
    Hao Huang
    Tian-Tian Tong
    Lee-Fong Yau
    Cheng-Yu Chen
    Jia-Ning Mi
    Jing-Rong Wang
    Zhi-Hong Jiang
    Scientific Reports, 6
  • [28] Synthetic paclitaxel-octreotide conjugate reverses the resistance of paclitaxel in A2780/Taxol ovarian cancer cell line
    Shen, Yang
    Zhang, Xiao-Yu
    Chen, Xi
    Fan, Li-Li
    Ren, Mu-Lan
    Wu, Yong-Ping
    Chanda, Kenneth
    Jiang, Shi-Wen
    ONCOLOGY REPORTS, 2017, 37 (01) : 219 - 226
  • [29] NF-κB activation contributes to anthracycline resistance pathway in human ovarian carcinoma cell line A2780
    Salvatore, C
    Camarda, G
    Maggi, CA
    Goso, C
    Manzini, S
    Binaschi, M
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2005, 27 (03) : 799 - 806
  • [30] Study on the Intervention Mechanism of Cryptotanshinone on Human A2780 Ovarian Cancer Cell Line Using GC-MS-Based Cellular Metabolomics
    Wang, Tong
    Yin, Shusheng
    Gu, Juan
    Li, Jingjing
    Zhang, Mengmeng
    Shan, Jinjun
    Wu, Xiao
    Li, Yongming
    PHARMACEUTICALS, 2023, 16 (06)